Podcasts about Outcomes research

Quando um novo medicamento ou tecnologia médica é aprovado por órgãos regulatórios, o caminho até sua disponibilização no sistema de saúde ainda envolve etapas decisivas. Uma das principais é a avaliação de custo-efetividade, base da economia da saúde.A ISPOR (International Society for Pharmacoeconomics and Outcomes Research) é a principal organização global dedicada ao avanço da economia da saúde e da pesquisa de desfechos em saúde. Ela reúne especialistas, gestores e formuladores de políticas para promover decisões baseadas em evidências sobre o valor de terapias e tecnologias médicas.Neste episódio do podcast Biotech and Health, Laura Murta e Camila Pepe conversam sobre o tema com Wilson Follador, presidente da ISPOR Brasil.

We kicked off the program with four news stories and different guests on the stories we think you need to know about!Rappell Boston - 100 People To Brave The Side of One of Cambridge's Biggest Buildings to Fight Epilepsy on Saturday, June 14, 2025. Josh Drew - Director of Development at Epilepsy Foundation New England and is in charge of the Rappel Event talked with Dan about the event.Boulder, Colorado antisemitic attack that injured a dozen. Adam Katz - president of Foundation to Combat Antisemitism checked in.Is sunscreen toxic? The war on sunscreen! Timothy Rebbeck, a professor of cancer prevention at Dana-Farber Cancer Institute has the answer.At-Home Heart Attacks and Cardiac Deaths on the Rise Since COVID-19 Pandemic, a recent study finds. Dr. Jason Wasfy – author of the published study on this & director of Outcomes Research at the Massachusetts General Hospital Cardiology Division and a faculty member at the Mongan Institute at Massachusetts General Hospital checked in.Listen to WBZ NewsRadio on the NEW iHeart Radio app and be sure to set WBZ NewsRadio as your #1 preset!

In this episode of the Scope of Things, host Deborah Borfitz brings you the latest news on AI-recommended precision dosing, organoid drug testing aiding treatment selection for bowel cancer, an AI tool for stratifying lung cancer patients, using HIV drugs to treat Alzheimer's disease, and the potential value of magic mushrooms to remedy the mood symptoms of Parkinson's. Blythe Adamson, international head of outcomes research and evidence generation at Flatiron Health, also joins in to discuss groundbreaking work harmonizing patient-level real-world data across four countries to enable multinational oncology research.  News Roundup CURATE.AI platform Article in Clinical Research News Study in npj Precision Oncology   FORECAST-2 clinical trial News on the Walter and Eliza Hall Institute website AI tool for sorting cancer patients Study in Nature Communications  HIV drugs for Alzheimer's protection Study in Alzheimer's & Dementia “Magic mushrooms” for Parkinson's disease Study in Neuropsychopharmacology Guest Blythe Adamson, Ph.D., international head of outcomes research and evidence generation at Flatiron Health  Flatiron Health enabling multinational oncology researh – article in Bio-IT World  Subscribe to the podcast on Apple Podcasts and leave a review to support the show. Join us at Scope Europe on October 14-15 in Barcelona - use code SOT10 for an additional 10% discount. GUEST BIO Blythe Adamson, PhD, MPH, Head of Outcomes Research and Evidence Generation, International at Flatiron Health & Founder of Infectious Economics Dr. Blythe Adamson is the head of international outcomes research and evidence generation at Flatiron Health.   As a visionary senior leader at Flatiron Health, her team pioneered deep learning language models for extraction of clinical details from EHR documents, breaking the limits of what was possible for humans to do alone. Learning from the experience of millions of patients with cancer, they generate evidence of treatment effectiveness and value used by governments around the world. Dr. Adamson co-invented a patented clinical decision-support tool, enabled by machine learning, that is used by cancer clinics to benefit patients.   She holds degrees in microbiology, epidemiology, and pharmaceutical economics with a focus on infectious disease prevention. Dr. Adamson has held roles at the Bill and Melinda Gates Foundation Institute for Disease Modeling, the NIAID HIV Vaccine Trials Network, and Flatiron Health. The Scope of Things podcast explores clinical research and its possibilities, promise, and pitfalls. Clinical Research News senior writer, Deborah Borfitz, welcomes guests who are visionaries closest to the topics, but who can still see past their piece of the puzzle. Focusing on game-changing trends and out-of-the-box operational approaches in the clinical research field, the Scope of Things podcast is your no-nonsense, insider's look at clinical research today.

Send us a textDr. Mirza Rahman, MD, MPH serves as the President of the American College of Preventive Medicine ( ACPM - https://www.acpm.org/about-acpm/governance/executive-officers/mirza-rahman/ ), a professional community, founded in 1954 as a professional community for board-certified physicians to network, share their expertise and advocate for the advancement of prevention. Today, ACPM represents over 2,000 physicians, medical students, non-physicians, and other partners. All believe in the importance of preventive medicine in our society. Dr. Rahman also serves as the Senior Vice President, Patient Safety & Pharmacovigilance at Cybin ( https://cybin.com/our-team/ ), a pharmaceutical company seeking to bring novel, second-generation psychedelics to market. He also and is a Co-Founder and President of the Guyanese Diaspora Charity ( https://www.guyanesediasporacharity.org/ ), a 501(c)(3) non-profit organization focused on helping to improve the lives of Guyanese. In addition, Dr. Rahman is an Adjunct Associate Professor of Epidemiology at Columbia University ( https://www.publichealth.columbia.edu/profile/mirza-i-rahman-md ) and as an Adjunct Associate Professor at the University of Guyana.Most recently, Dr. Rahman was the Vice President & Chief Safety Officer at Organon, a global healthcare company. There, he was responsible for leading and setting the broad strategic direction for pharmacovigilance for this multinational company.Prior to that, Dr. Rahman was the Senior Vice President, Chief Global Pharmacovigilance Officer & European Research & Development Lead at Otsuka Pharmaceuticals, a global Japanese based pharmaceutical company. In 2013, he created the ACPM - Otsuka Pharmacovigilance Physician Program in Global Medical Safety. Dr. Rahman joined Otsuka from Merck Research Laboratories, where he was an Executive Director in the Clinical Risk Management/Global Safety department. Before this, he worked at Johnson & Johnson in a variety of positions, serving as a Worldwide Vice President, Health Economics & Reimbursement at Ortho-Clinical Diagnostics in his last role there.During his 25+ years in the pharmaceutical industry, while Dr. Rahman has worked primarily in Pharmacovigilance, he has also worked in Medical Affairs, Medical Information, Health Economics and Outcomes Research, Quality Management, Clinical Development, Manufacturing, and Regulatory Affairs.Dr. Rahman completed his Public Health & General Preventive Medicine Residency along with his Family Medicine Residency at Stony Brook University. He completed the Advanced Management Program at the Columbia Business School and earned his Master of Public Health degree from the Columbia University School of Public Health. Dr. Rahman earned his Doctor of Medicine degree from the Stony Brook University School of Medicine, and his Bachelor of Science degree from the Sophie Davis School of Biomedical Education at the City College of the City University of New York. #MirzaRahman #AmericanCollegeOfPreventiveMedicine #PatientSafety #Pharmacovigilance #GuyaneseDiasporaCharity #Epidemiology #ColumbiaUniversity #UniversityOfGuyana #MedicalAffairs #HealthEconomics #OutcomesResearch #QualityManagement #ClinicalDevelopment #RegulatoryAffairs #PublicHealth #BrainHealth #DiabetesPrevention #ReducingHypertension #LifestyleMedicine #PopulationHealth #ViolencePrevention #Psychedelics #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #Podcasting #ViralPodcast #STEM #Innovation #Science #Technology #ResearchSupport the show

Send us a textDr. Blythe Adamson, PhD, MPH ( https://www.blytheadamson.com/ ) is Head of Outcomes Research and Evidence Generation at Flatiron Health ( https://flatiron.com/ ), where her work has been focused on developing deep learning language models for extraction of clinical details from EHR documents, ultimately learning from the experience of millions of patients with cancer, and generating evidence of treatment effectiveness and value used by governments around the world. Dr. Adamson is a scientist, epidemiologist and economist ( https://scholar.google.com/citations?user=jAflVcUAAAAJ&hl=en ), who co-invented a patented clinical decision-support tool, enabled by machine learning, that is used by cancer clinics to benefit patients.Formerly a lead data scientist in the West Wing of The White House, Dr. Adamson has been involved in advising public and private institutions including professional sports leagues, the entertainment industry, retailers, manufacturers, and more.Dr. Adamson founded the company Infectious Economics ( https://www.infectiouseconomics.com/ ), with a focus to provide thought leadership to policy makers and industry leaders on cost-effective strategies to prevent the transmission of viruses.Dr. Adamson holds degrees in microbiology, epidemiology, and pharmaceutical economics with a focus on infectious disease prevention, doing her Master of Public Health in Epidemiology, and Ph.D. in Pharmaceutical Outcomes Research and Policy, at the University of Washington, where she still lectures as an Affiliate Assistant Professor ( https://sop.washington.edu/people/blythe-adamson/ ).Dr. Adamson has also held roles at the Bill and Melinda Gates Foundation Institute for Disease Modeling and the NIAID HIV Vaccine Trials Network and is a Board Member of NBA-funded SalivaDirect lab at Yale.#BlytheAdamson #FlatironHealth #EHR #Oncology #Cancer #HIV #InfectiousEconomics #RWE #RealWorldEvidence #ElectronicHealthRecords #RealWorldData #ClinicalDecisions #HealthPolicies #LargeLanguageModels #LLM #AI #ArtificialIntelligence #MachineLearning #ML #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Aasma Shaukat, MD, MPH While fecal immunochemical testing and multitarget stool DNA testing are commonly used to screen for colon cancer, screening rates remain low throughout the United States. With the introduction of blood-based testing modalities, noninvasive colon cancer screening is becoming more accessible than ever. Join host Dr. Peter Buch and Dr. Aasma Shaukat as they discuss the effectiveness of current and emerging methods as well as best practices for screening patients. Dr. Shaukat is the Robert M. and Mary H. Glickman Professor of Medicine at the NYU Grossman School of Medicine and the Co-Director of Translational Research, Education, and Careers and the Director of Outcomes Research in the Division of Gastroenterology and Hepatology at NYU.

How do we ensure that healthcare is accessible, effective, efficient, and affordable for all? How can a professional society shape global health policy while advancing scientific research?In this episode of Associations Thrive, host Joanna Pineda interviews Rob Abbott, CEO of ISPOR. Rob discusses:ISPOR's role as the professional society for Health Economics and Outcomes Research (HEOR), with a global reach spanning over 100 countries and 20,000 members.How ISPOR is a multi-stakeholder society that includes clinicians, researchers, policymakers, industry professionals, and investors, creating a broad and impactful membership base.The importance of health economics and outcomes research in informing healthcare policy and improving patient outcomes worldwide.ISPOR's recent rebranding from the International Society for Pharmacoeconomics and Outcomes Research to ISPOR – The Professional Society for Health Economics and Outcomes Research, making the organization more inclusive of healthcare professionals.The launch of ISPOR's 2030 strategic plan, which features a bold vision for a world where healthcare is accessible, effective, efficient, and affordable for all.How ISPOR is shifting from primarily curating scientific research to actively engaging in health policy discussions and advocating for evidence-based decision-making.The upcoming launch of ISPOR's Institute for Global Health in 2025, which will focus on emerging healthcare challenges and horizon scanning for high-impact policy interventions.How ISPOR is strengthening its global chapters and partnerships to ensure local expertise informs global policy.The evolution of ISPOR's conferences, including record-breaking attendance and new events in Asia and Latin America to expand engagement in underserved regions.How ISPOR is working to redefine the concept of ‘value' in healthcare, incorporating social determinants of health and a more holistic approach to decision-making.References:ISPOR WebsiteMusic from #Uppbeat (free for Creators!):https://uppbeat.io/t/paul-yudin/quiet-flightLicense code: KJRRI6GHC7WKCLDT

This podcast explores the intersection of pharmacy and technology, focusing on how machine learning (ML) models are being used to predict medication non-adherence in patients with inflammatory bowel disease (IBD). Dr. Gina Luchen, Director of Digital Health and Data at ASHP and Dr. Christian Rhudy, Associate Director of Quality and Outcomes Research at the University of Kentucky HealthCare discuss Dr. Rhudy's recent ML model research, key findings, and the potential applications of these models across different patient populations. The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Increased Grain Futures Prices Extending Days-On-Feed, Economic Considerations Here Comes More Snow   00:01:05 – Increased Grain Futures Prices: Dan O'Brien, K-State grain economist, kickstarts today's show with his grain market outlook. He discusses the higher futures prices and if they influenced cash prices. Dan O'Brien on AgManager.info   00:12:05 – Extending Days-On-Feed, Economic Considerations: Continuing the show is research associate for the Center for Outcomes Research and Epidemiology at K-State Lucas Horton as he explains recent research that looked into extending days on feed of feedlot steers. lhorton@ksu.edu  Extending Days-on-Feed of Feedlot Steers - AgManager.info   00:23:05 – Here Comes More Snow: K-State meteorologist Chip Redmond concludes the show with a weather forecast. He says where in Kansas is likely to see snow in the next week.     Send comments, questions or requests for copies of past programs to ksrenews@ksu.edu.   Agriculture Today is a daily program featuring Kansas State University agricultural specialists and other experts examining ag issues facing Kansas and the nation. It is hosted by Shelby Varner and distributed to radio stations throughout Kansas and as a daily podcast.   K‑State Research and Extension is a short name for the Kansas State University Agricultural Experiment Station and Cooperative Extension Service, a program designed to generate and distribute useful knowledge for the well‑being of Kansans. Supported by county, state, federal and private funds, the program has county Extension offices, experiment fields, area Extension offices and regional research centers statewide. Its headquarters is on the K‑State campus in Manhattan

Chapter 1 What's Parent Effectiveness Training by Thomas GordonParent Effectiveness Training (PET), developed by Thomas Gordon in the 1960s, is a comprehensive approach designed to assist parents in fostering better relationships with their children through effective communication. The program emphasizes the importance of active listening, respectful dialogue, and problem-solving skills. Gordon's methods focus on understanding children's needs and feelings, promoting self-directed learning, and encouraging children to express their thoughts and emotions freely.The PET framework advocates for a non-punitive approach to discipline, shifting away from traditional authoritarian methods to a more collaborative family dynamic. Parents are taught to engage in cooperative problem-solving sessions, helping children learn accountability and responsibility while strengthening their emotional connections. The training includes practical exercises, role-playing scenarios, and real-life applications to ensure that parents can effectively implement the strategies in their daily lives. Overall, PET aims to develop a supportive environment that nurtures children's emotional and psychological well-being.Chapter 2 Parent Effectiveness Training by Thomas Gordon SummaryParent Effectiveness Training (PET) by Thomas Gordon: Summary Overview: Parent Effectiveness Training, developed by psychologist Thomas Gordon in the 1960s, is a program designed to help parents improve their communication and conflict-resolution skills with their children. It emphasizes the importance of fostering a nurturing environment while encouraging children to express their feelings and develop a sense of responsibility. The program combines principles of psychology with practical approaches that are easy for parents to implement.Key Concepts: Effective Communication: The foundation of PET is effective communication, which involves active listening, empathy, and openness. Parents are taught to focus on understanding their children's feelings and perspectives without immediately reacting or correcting them.I-Statements: Gordon emphasizes the use of "I-statements" instead of "you-statements" to express feelings without placing blame. For example, saying "I feel frustrated when you leave your toys out" is more constructive than saying "You never clean up your toys."Conflict Resolution: The program teaches parents how to manage conflicts positively. The goal is to resolve issues in a manner that respects both parent and child needs. Gordon introduces a conflict-resolution model to help parents find mutually acceptable solutions through discussion and negotiation.Problem Ownership: Parents are encouraged to help their children learn to own their problems. Instead of solving every issue for their children, parents should guide them toward finding their own solutions. This builds children's confidence and decision-making skills.Active Listening: Active listening is a critical skill emphasized in PET. Parents are taught to listen intently to their children's concerns and feelings, reflecting back what they've heard to confirm understanding.Parenting Styles: The program highlights different parenting styles (authoritative, permissive, authoritarian) and promotes a collaborative and accepting approach that fosters children's independence and self-esteem.Program Structure: PET workshops consist of a series of sessions where parents learn through discussion, role-playing, and practical exercises. The curriculum covers the concepts mentioned above and provides tools and activities to practice these skills. Outcomes: Research suggests that parents who undergo PET report better relationships with their children, lower levels of conflict, and increased satisfaction in their parenting roles....

As is customary, HUD released its annual report on homelessness at the end of 2024. It revealed a startling year-over-year increase in homelessness among individuals and families in the United States. Among the devastating data, there were bright spots such as a decrease in homeless veterans. But the reporting and punditry surrounding the report was less than stellar, and the news was buried in a matter of days. Crucially, some of the worst reporting on HUD’s findings came from left wing media sources who pointed to immigration as one of the drivers of the increase, conveniently and uncritically parroting conservative talking points while ignoring the more pertinent narratives. Chapters Intro: 00:00:37 Chapter One: A Point in Time. 00:03:12 Chapter Two: Whether Building a Home or a Narrative, Framing Matters. 00:07:39 Chapter Three: Housing First: When Evidence Meets Ideology. 00:17:03 Bring it Home, Max. 00:26:20 Post Show Musings: 00:30:55 Outro: 00:58:21 Resources HUD: The 2024 Annual Homelessness Assessment Report (AHAR) to Congress Tsemberis, S., & Eisenberg, R. F. (2000). Pathways to Housing: Supported Housing for Street-Dwelling Homeless Individuals with Psychiatric Disabilities National Alliance to End Homelessness. (2000). A Plan, Not a Dream: How to End Homelessness in Ten Years. Washington, DC U.S. Interagency Council on Homelessness. (2010). *Opening Doors: Federal Strategic Plan to Prevent and End Homelessness. Washington, DC Department of Housing and Urban Development. (2014). Housing First in Permanent Supportive Housing Brief Gillespie, S., et al. (2021). Denver Supportive Housing Social Impact Bond Initiative: Final Outcome Report. Urban Institute Los Angeles County Department of Health Services. (2019). Housing for Health Year Four Evaluation Report Wright, B. J., et al. (2016). Health in Housing: Exploring the Intersection between Housing and Health Care. Center for Outcomes Research and Education National Academies of Sciences, Engineering, and Medicine. (2018). Permanent Supportive Housing: Evaluating the Evidence for Improving Health Outcomes Among People Experiencing Chronic Homelessness Gubits, D., et al. (2016). Family Options Study: 3-Year Impacts of Housing and Services Interventions for Homeless Families. U.S. Department of Housing and Urban Development Y-Foundation. (2020). A Home of Your Own: Housing First and Ending Homelessness in Finland National Alliance to End Homelessness. (2020). Rapid Re-Housing Works: What the Evidence Says Padgett, D. K., et al. (2016). Housing First: Ending Homelessness, Transforming Systems, and Changing Lives. Oxford University Press UNFTR Episode Resources Over The Borderline Series: Introduction. Part One. Part Two. Part Three. -- If you like #UNFTR, please leave us a rating and review on Apple Podcasts and Spotify: unftr.com/rate and follow us on Facebook, Bluesky, TikTok and Instagram at @UNFTRpod. Visit us online at unftr.com. Buy yourself some Unf*cking Coffee at shop.unftr.com. Check out the UNFTR Pod Love playlist on Spotify: spoti.fi/3yzIlUP. Visit our bookshop.org page at bookshop.org/shop/UNFTRpod to find the full UNFTR book list, and find book recommendations from our Unf*ckers at bookshop.org/lists/unf-cker-book-recommendations. Access the UNFTR Musicless feed by following the instructions at unftr.com/accessibility. Unf*cking the Republic is produced by 99 and engineered by Manny Faces Media (mannyfacesmedia.com). Original music is by Tom McGovern (tommcgovern.com). The show is hosted by Max and distributed by 99. Podcast art description: Image of the US Constitution ripped in the middle revealing white text on a blue background that says, "Unf*cking the Republic."Support the show: https://www.buymeacoffee.com/unftrSee omnystudio.com/listener for privacy information.

Rob Abbott, CEO and Executive Director at ISPOR, the Professional Society for Health Economics and Outcomes Research, focuses on defining and measuring value in healthcare, including accessibility, affordability, effectiveness, and patient outcomes. HEOR (health economics and outcomes research) can provide data-driven insights to guide healthcare decision-making, reduce bias in research, and consider a broader range of factors like social determinants of health. This can improve treatment adherence, align therapies with what matters most to patients, and support the evaluation of technology used for treatments and predictive analysis of new therapies.   Rob explains, "I'm excited at both the legacy of work that health economics and outcomes research has contributed to, but I'm particularly excited about the extent to which health economics and outcomes research can provide data-driven insights to highlight health interventions that provide the best health outcomes for the investment made. This is good for managing the expenditure of public resources. Still, even more so, data-driven insights can help us lead to better health outcomes, better treatment protocols, and better health outcomes for patients." "As health economists and a professional society representing health economists and outcomes researchers, I think we know that historically, we have defined value quite narrowly in terms of a person's physical health, for instance. But we know that increasingly the concept of whole health or a more holistic approach to health is gaining a lot of traction. So, we are actively engaged in expanding the definition of health to include access to housing, social connections and networks, healthy food and lifestyle choices, and things of that nature. So, I think we are beginning to bring some new ideas to the table in terms of how we think about health."  #ISPOR #Patients #Healthcare #DigitalHealth #GlobalHealth #HEOR #RWE #HealthEconomics #HealthAI #DrugPriceNegotiations ISPOR.org Download the transcript here

Rob Abbott, CEO and Executive Director at ISPOR, the Professional Society for Health Economics and Outcomes Research, focuses on defining and measuring value in healthcare, including accessibility, affordability, effectiveness, and patient outcomes. HEOR (health economics and outcomes research) can provide data-driven insights to guide healthcare decision-making, reduce bias in research, and consider a broader range of factors like social determinants of health. This can improve treatment adherence, align therapies with what matters most to patients, and support the evaluation of technology used for treatments and predictive analysis of new therapies.   Rob explains, "I'm excited at both the legacy of work that health economics and outcomes research has contributed to, but I'm particularly excited about the extent to which health economics and outcomes research can provide data-driven insights to highlight health interventions that provide the best health outcomes for the investment made. This is good for managing the expenditure of public resources. Still, even more so, data-driven insights can help us lead to better health outcomes, better treatment protocols, and better health outcomes for patients." "As health economists and a professional society representing health economists and outcomes researchers, I think we know that historically, we have defined value quite narrowly in terms of a person's physical health, for instance. But we know that increasingly the concept of whole health or a more holistic approach to health is gaining a lot of traction. So, we are actively engaged in expanding the definition of health to include access to housing, social connections and networks, healthy food and lifestyle choices, and things of that nature. So, I think we are beginning to bring some new ideas to the table in terms of how we think about health."  #ISPOR #Patients #Healthcare #DigitalHealth #GlobalHealth #HEOR #RWE #HealthEconomics #HealthAI #DrugPriceNegotiations ISPOR.org Listen to the podcast here

Professor Erica Spatz MD talks to Dr Funmi Okunola MD about the effects of Long COVID on the heart. Professor Spatz is a cardiologist and clinical investigator at the Centre for Outcomes Research and Evaluation. She is the Associate Professor of Cardiology and Associate Professor of Epidemiology at Yale School of Medicine in the USA and is the Director of the Preventative Cardiovascular Health Program. REFERENCES1.Shah SM, Odanovic N, Kunnirickal S, Feher A, Pfau SE, Spatz ES. Chest pain and coronary endothelial dysfunction after recovery from COVID‐19: A case series. Clinical Case Reports. 2022 Apr;10(4):e05612.2.HilserJR, Spencer NJ, Afshari K, Gilliland FD, Hu H, Deb A, Lusis AJ, Wilson Tang WH, Hartiala JA, Hazen SL, Allayee H. COVID-19 Is a Coronary Artery Disease Risk Equivalent and Exhibits a Genetic Interaction With ABO Blood Type. Arteriosclerosis, Thrombosis, and Vascular Biology. 2024 Nov;44(11):2321-33.

In this episode of the Alliance Podcast, Almanac Editorial Board Editor-in-Chief and Chair Erin Schwarz sits down with Alliance 2025 Planning Committee Chair Ailene Cantelmi for a behind-the-scenes look at the upcoming conference. Listen in as Ailene highlights why transparency, elevating posters and outcomes, and practicing what we preach as educators were key elements of planning the Alliance 2025 Annual Conference. After you listen, be sure you are registered for #Alliance25, taking place Jan. 8–11 in Orlando, Florida. || LINKS *Episode* https://www.acehp.org/Annual-Conference | https://almanac.acehp.org/Education/Education-Article/a-house-we-build-together *Alliance Websites* https://www.acehp.org/ | https://almanac.acehp.org/

In this episode, Dr. Steve Gard, editor-in-chief of the Journal of Prosthetics and Orthotics, chats with Eric Weber, LCPO, FAAOP, and Glen Thompson, MS, CPO. They delve into the essential work of the Academy's Outcomes Research Committee (ORC), discussing how the ORC helps Academy members effectively gather, use, and report outcome measures in clinical practice. They also explore the committee's role in raising awareness, promoting the application of outcome measures, facilitating data dissemination, and fostering collaboration between researchers and clinicians.   Show notes This month's episode features the Academy's Outcomes Research Committee (ORC) and highlights the committee's work to generate two important resources. We invite Academy members to access these valuable resources below: Outcome Measures Toolkits  How-to-Videos   O&P Research Insights is produced by Association Briefings.  

Throughout this podcast, we've explored many facets of what makes science and health so interdisciplinary. Today, we're adding one more factor to the mix: philosophy. Specifically, we'll be joined by Dr. Brennan Spiegel to learn about the future of virtual reality in new medical technologies and how it can be informed by a philosophical approach to tackle complex questions emerging from this field. Tune in to discover the ever-evolving nature of medical technology, how virtual reality can be used for mental health applications, and what human consciousness really means.Dr. Brennan Spiegel directs the Cedars-Sinai Center for Outcomes Research and Education (CS-CORE) to develop one of the largest medical VR programs and support the emerging field of Medical Extended Reality (MXR). Along with authoring many medical textbooks and over 270 articles in peer-reviewed journals, he published the best-selling book VRx: How Immersive Therapeutics Will Revolutionize Medicine in 2020.Read Dr. Spiegel's book here: www.amazon.com/VRx-Virtual-Therapeutics-Revolutionize-Medicine/dp/1541699769Check out Xaia, the mental health VR app developed by Dr. Spiegel's team: xaia.health/

"[Health equity] is a term that we often listen to, but it involves so many things," says Frans Serpa, MD, Smith Center for Outcomes Research in Cardiology. On this podcast, Serpa discusses his innovative work at the intersection of cardiology, health equity, and health economics. Tune in to learn more about how common heart conditions and outcomes are evaluated through epidemiology and cost analysis. Transcript: https://bit.ly/4d6mmJ0

In the 51st episode of the #RehabCast, our host Dr. Bill Niehaus first meets with Maheen M. Adamson, PhD, MHL to discuss A Vision Neuroscience-Based Communication & Detection Solution for “The Speechless” (https://acrm.org/acrm-communities/technology/launchpad/acrm-launchpad-2023-winners/). Dr Niehaus then welcomes Anne Deutsch PhD, RN, CRRN and Raj Kumar PhD MPH to look into Trends in the Characteristics and Outcomes of Older Medicare Patients with Traumatic Brain Injury Treated in Inpatient Rehabilitation Facilities: 2013 to 2018 (https://doi.org/10.1016/j.apmr.2024.02.716).

Howie and Harlan are joined by Lisa Suter, a rheumatologist and the senior director of the Quality Measurement Program at Yale's Center for Outcomes Research & Evaluation. Harlan reflects on the meaning of Juneteenth and reports on a Yale-led report card on health equity; Howie comments on Surgeon General Vivek Murthy's call for warning labels on social media.  Links: Juneteenth National Museum of African American History & Culture: Juneteenth Harlan Krumholz: “Excess Cardiovascular Mortality Among Black Americans 2000-2022: A JACC Report Card” “JACC Report Card Highlights Inequities in CV Care, Death Rates” Harlan Krumholz: “Excess Mortality and Years of Potential Life Lost Among the Black Population in the US, 1999-2020” Lisa Suter Center for Outcomes Research and Evaluation National Institute of Arthritis and Musculoskeletal and Skin Disease: Arthritis Lisa Suter: “Medical Decision Making in Patients With Knee Pain, Meniscal Tear, and Osteoarthritis” Lisa Suter: “Projecting Lifetime Risk of Symptomatic Knee Osteoarthritis and Total Knee Replacement in Individuals Sustaining a Complete Anterior Cruciate Ligament Tear in Early Adulthood” “Voices of DEI: Lisa Suter, MD” Harlan Krumholz: “Association of door-to-balloon time and mortality in patients admitted to hospital with ST elevation myocardial infarction: national cohort study” Harlan Krumholz: “Association of Racial and Socioeconomic Disparities With Outcomes Among Patients Hospitalized With Acute Myocardial Infarction, Heart Failure, and Pneumonia An Analysis of Within- and Between-Hospital Variation” The Surgeon General on Social Media  “Surgeon General: Why I'm Calling for a Warning Label on Social Media Platforms” “Social Media and Youth Mental Health: The U.S Surgeon General's Advisory” Kids Online Safety Act: Senator Richard Blumenthal Learn more about the MBA for Executives program at Yale SOM. Email Howie and Harlan comments or questions.

This week on EJB Talks Stuart Shapiro talks to public health alumnus Christopher Black, Ph.D. Also a member of the Bloustein School Advisory Board who now works Senior Director, Real-World Evidence & Outcomes Research at Merck & Co., Inc., Chris shares his story of pursuing a public health degree after struggling with organic chemistry. With guidance from mentor Dr. Dona Schneider, retired Bloustein School professor and associate dean, Chris took a few years to work and teach before getting an advanced degree in public health, focusing on epidemiology and biostatistics. He also explains his 13-year career at Merck in health economics and outcomes research, where he helps design studies and evaluate new therapies, including individualized cancer treatment. Chris emphasizes how a public health background provides intellectual stimulation across industries and topics, encouraging soon-to-be graduates of the school to take every opportunity as a learning experience.  --- Send in a voice message: https://podcasters.spotify.com/pod/show/ejbtalks/message

Dr. Charlotte Owens is sharing with Jackie the societal inequities she witnessed firsthand and how they have shaped her commitment to making a difference. From understanding real-life factors that impact health to the disparities in maternal health outcomes, the Senior Vice President and Head of Global Medical Affairs and Outcomes Research at Organon emphasizes the need for a more inclusive healthcare system that empowers women to advocate for their well-being. Tune in to hear what Dr. Owens and Organon are doing to address systemic biases in healthcare, learn actionable steps for advocating for your health, and understand the importance of speaking up, asking questions, and seeking support. "Diversity Beyond the Checkbox" is presented by The Diversity Movement and hosted by Inc 200 Female Founders award winner, Jackie Ferguson.  Check out exclusive bonus content on BeyondtheCheckbox.com! This show is proud to be a part of The Living Corporate Network and to be produced by Earfluence.

A cancer diagnosis and the treatment that follows can trigger stress and anxiety. Camille is joined this week by Dr. Abby Rosenberg, an expert in helping AYA cancer patients manage stress. They chat about why being diagnosed as an adolescent/young adult has particular challenges, tools and techniques for managing stress, and how palliative care is different from hospice care (spoiler alert - it's not just for end of life care!). Listen in to learn why stress is normal, the three categories of resilience resources, the power of distraction, the benefit of emotions, and how palliative care helps the entire care team focus on what is important to the patient. Abby R. Rosenberg, MD, MS, MA, joined the team at Boston Children's Hospital as the Director of Palliative Care in 2023. She is also the Chief of Pediatric Palliative Care at the Dana-Farber Cancer Institute. Prior to that, she was at the University of Washington and Seattle Children's Hospital, where she served as the Director of Survivorship and Outcomes Research and Director of Pediatrics at the Cambia Palliative Care Center of Excellence. Both Dr. Rosenberg's clinical approach and her research focus on helping people facing serious illness to live their best lives, for as long as possible. Specifically, she and her team develop programs that help patients and families build resilience and optimize their quality of life.

David Higgins is a research fellow and investigator at the Adult and Child Center for Outcomes Research and Delivery Science and a general academic pediatrician in the Department of Pediatrics at the University of Colorado School of Medicine and Children's Hospital Colorado. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. D.M. Higgins and S.T. O'Leary. The Risks of Normalizing Parental Vaccine Hesitancy. N Engl J Med 2024;390:485-487.

Disease. Sickness. Malady. These are words that can truly send a chill down the spine as they bring us to the reality of the fragility of life and our proximity to the brink of death. Greek physician Hippocrates, known as the "father of medicine" from the 4th century BC, was the first known person to investigate the reasoning behind disease and its relationship with environmental factors. What exactly is a disease? Is there a common denominator of why they happen? Is there a way to evade sickness and possibly attain everlasting life? In this episode, we investigate the science and nature of sickness with a disease scientist, specifically in light of the current novel coronavirus pandemic. We are joined today by Dr. Katrine Wallace, also known as Epidemiologist Kat, a scientist with expertise in epidemiology, research methodology, biostatistics, and science communication. She received her PhD in Epidemiology from the University of Illinois at Chicago, where she currently serves as an Adjunct Assistant Professor of Epidemiology and Biostatistics. In 2022, she became Certified in Public Health by the National Board of Public Health Examiners. Previously a Director for several medical device companies' Global Health Economics and Outcomes Research departments, Dr. Wallace now stands as an Advisory Board member for various projects focusing on infectious disease and public health practitioners funded by The Centers for Disease Control and Prevention. During the commencement of the 2019 pandemic, she provided public education and health misinformation debunking online, tackling the novel coronavirus, contagion data, and masking and immunization efforts. Dr. Wallace has become part of international science communication initiatives, such as “Team Halo” by the United Nations and Project FIDES by the World Health Organization. The UK government also recognized her as a “Vaccine Luminary” at the 2021 G7 Vaccine Confidence Summit. Dr. Wallace has extended her education in the classroom and online to international television as an expert opinion contributor for outlets such as BBC World News, CNN, CBS, The Washington Post, The New York Times, MSNBC, and NPR.Livestream Air Date: April 11, 2023Follow Katrine Wallace, PhD, CPH: Website, Instagram, X, FacebookFollow Friends of Franz Podcast: Website, Instagram, FacebookFollow Christian Franz Bulacan (Host): Instagram, YouTubeThankful to the season's brand partners: Covry, House of M Beauty, Nguyen Coffee Supply, V Coterie, Skin By Anthos, Halmi, By Dr Mom, LOUPN, Baisun Candle Co., RĒJINS, Twrl Milk Tea, 1587 Sneakers

This week on *The Heart of Innovation* Hosted by Interventional Cardiologist Dr. John Philips and Emmy Award Winning Journalist Kym McNicholas, The focus is on groundbreaking treatment for hard-to-treat blood pressure. The featured guest is Interventional Cardiologist Dr Eric Secemsky, Director of Vascular Intervention at BIDMC and Section head of Intervetional Cardiology and Vascular research at the Richard. A. and Susan F. Smith Center for Outcomes Research in Cardiology at BIDMC. Dr. Secemsky delves into the prevalence of high blood pressure, affecting nearly half of American adults, with many being unaware of their condition or facing challenges in consistently accessing or adhering to medications. Shockingly only one in four individuals with high blood pressure have it under control, underscoring the urgency of addressing this public health concern. The discussion highlights the subset of patients facing treatment resistant hypertension, where standard medication prove ineffective or intolerable, posing increased risks of heart of disease, stroke, and cardiovascular complications. Dr. Secemsky introduces the pioneering procedure of renal denervation (RDN), which involves permanently disrupting the nerves, controlling the kidneys' arteries. This innovative approach, developed, offers a potential solution for bringing treatment resistant hypertension back under control, offering hope for patients facing persistent challenges in managing their condition. The episode provides a comprehensive exploration of the groundbreaking RDN procedure, offering valuable insights into a first-of-its kind treatment for high blood pressure. Dr. Secemsky's expertise and the innovative advancements in cardiovascular care showcased in this episode underscore the ongoing pursuit of transformative solutions in the field of interventional cardiology. Tune into * The Heart Of Innovation* for an in-depth discussions on this breakthrough treatment for hypertension and its potential impact on reshaping the landscape of vascular care.

One of the bravest doctors in the country, Florida's Surgeon General, Dr. Joseph Ladapo, joins the program to discuss his new book "Transcend Fear: A Blueprint for Mindful Leadership in Public Health". We also discuss the situation that is quickly forming against the mRNA producing companies due to the massive side effects and new and ongoing lawsuits. Lastly we discuss his personal situation and how he became who he is today. You can buy a copy of his book at https://www.skyhorsepublishing.com/9781510774711/transcend-fear/ or at many other book retailers. Links mentioned in the show: Help fight human trafficking while boosting your kids immune system with Z-stack Kids – learn more at https://zstacklife.com/products/z-stack-kids?ref=Sarah&variant=41579270897830 Explore the extraordinary benefits of Leela's tech @ https://leelaq.com/?ref=sarahw – Use code sarah10 to save 10% Turn back time with NuM8Trx, the world's most effective collagen building treatment. But now at https://purebellavita.com/pages/sarah-num8trx - Use code “XmasSarah” to save 20%   Consider subscribing: Follow on Twitter @Sarah_Westall Follow on my Substack at SarahWestall.Substack.com See Important Proven Solutions to Keep Your from getting sick even if you had the mRNA Shot - Dr. Nieusma MUSIC CREDITS: “In Epic World” by Valentina Gribanova, licensed for broad internet media use, including video and audio       See on Bastyon | Bitchute | Odysee | Rumble | Youtube | Freedom.Social   Surgeon General, Dr. Joseph Ladapo Biography Joseph A. Ladapo, MD, PhD, is the State Surgeon General of Florida. He also serves as Professor of Medicine at the University of Florida, where his research examines behavioral economic strategies to reduce cardiovascular risk in low-income and disadvantaged populations. Clinically, he has cared primarily for hospitalized patients. His research program has been supported by the National Institutes of Health and Robert Wood Johnson Foundation, and includes clinical trials of interventions for weight loss, smoking cessation, and cardiovascular disease prevention among people with HIV. Dr. Ladapo's studies have been published in leading medical journals, including The Journal of the American Medical Association, Journal of the American College of Cardiology, and Annals of Internal Medicine. His writings about health policy and public health have appeared in the Washington Post, Wall Street Journal, and USA Today. Prior to joining the faculty of University of Florida, he was a tenured Associate Professor at David Geffen School of Medicine at the University of California, Los Angeles (UCLA) Dr. Ladapo graduated from Wake Forest University and received his medical degree from Harvard and PhD in Health Policy from Harvard Graduate School of Arts and Sciences. He completed his clinical training in internal medicine at the Beth Israel Deaconess Medical Center, where he received the Harvard Medical School Class of 2012 Resident Teaching Award and the Daniel E. Ford Award in Health Services and Outcomes Research from John Hopkins University.    

Robert Yeh is a professor of medicine at Harvard Medical School and director of the Smith Center for Outcomes Research at Beth Israel Deaconess Medical Center. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. K.T. Kadakia, D.B. Kramer, and R.W. Yeh. Coverage for Emerging Technologies — Bridging Regulatory Approval and Patient Access. N Engl J Med 2023;389:2021-2024.

In today's rapidly evolving healthcare landscape, the collaboration between science and business is pivotal in improving patient outcomes and advancing medical innovation.The harmonious partnership between science and business in healthcare holds the potential to revolutionize patient care. By working together, we can ensure that patients receive the best possible treatments and services, ultimately improving their quality of life. We are honored to have Setareh A. Williams on our show as she shares her life journey as a scientist dedicated to helping patients. Setareh A. Williams, PhD, CMPP™ has more than 20 years of US and global experience in strategic planning, product launch, medical affairs, research and analytics, and scientific communication. She has a proven track record of achievement and delivery of evidence to support multiple product launches and in-line brands at large companies and start-ups across joint-venture and alliance collaborations. Setareh earned her Ph.D. in Chronic Disease Epidemiology from Yale University and her B.S. in Biological Sciences and French Literature from University of California at Los Angeles. Prior to finding Star Biopharma Consulting, LLC., Setareh was the Head of Global Health Economics and Outcomes Research at Radius Health. Earlier in her career she held various roles within big pharma driving significant initiatives at Pfizer, AstraZeneca, and Novartis. She has published extensively in epidemiology, outcomes research, patient experience, adherence, and comparative effectiveness and cost-effectiveness.

Tina Loarte-Rodriguez is dedicated to leaving the world a little better than she finds it. She is an eternal optimist who believes in the power of community, kindness, and growth.    Her professional experience includes teaching and over seventeen years of nursing in various healthcare settings and specialties. She is the Associate Director of Health Equity Measures at the Yale Center for Outcomes Research and Evaluation (CORE). Tina works with talented clinical investigators, statisticians, analysts, computer scientists, economists, epidemiologists, management experts, and administrative staff, actively collaborating with national and international experts in health equity measures and outcomes research.    A first-generation college graduate, she is a graduate of Cornell University, UCONN, and Quinnipiac University. A perpetual learner passionate about innovation, health equity, and advocacy, she participates in the American Nurses Association's Innovation Accelerator Program and will be a fellow of the American Nurses Advocacy Institute in the fall.   Tina is a Hartford Business Journal Healthcare Hero Award and the Ct Nursing Association Excellence in Team Award winner. She is active with the National Association of Hispanic Nurses- Hartford Chapter, the CT Nursing Association, and DNPs of Color. Tina is a featured author in Hispanic Stars Rising Vol. III and is extremely proud of her most recent work, Latinas in Nursing, a collection of stories of determination, inspiration, and trust.  Check out the website: Latinasinnursing.com Tina works hard, and she plays even harder. She loves dancing, traveling, and reading. An Afro-Latina Boricua, born and raised in the Bronx, NY, she now resides in CT with her incredibly supportive husband, their three phenomenal children, her father, and two rescue dogs.Connect with Tina on:Website: www.Latinasinnursing.com Join the conversation by sending comments or questions to hello@stressblueprint.com. 1. Subscribe to the Nurse Wellness Podcast2. Download your FREE resource 3 Questions to Ask When You're Stressed3. Join the Wellness Hub for Stress Solutions community4. Email Nurse Wellness Podcast at hello@stressblueprint.comIntro and outro music produced by DNMbeats

Dr. David Penson, Chair of the Department of Urology at Vanderbilt University, discusses his comparative effectiveness research in prostate cancer. In the second of our two-part prostate cancer series, we delve deeper into the world of prostate cancer treatment decision-making. Dr. Penson discusses the emotional and informational hurdles that patients face, as well as the importance of patient education, understanding patient preferences, and the ongoing battle against overtreatment in prostate cancer.  Key Highlights: Importance of informed decision making and arming patients with accurate and reliable information. Understanding the concept of patient preferences in treatment decision making. Overcoming decision biases and how the emotion of a cancer diagnosis can outweigh a rational decision-making process. About our guest: David F. Penson, MD, MPH is the Hamilton and Howd Chair in Urologic Oncology, Director of the Center for Surgical Quality and Outcomes Research and Professor and Chair, Department of Urology at Vanderbilt University. He currently maintains a clinical practice in urologic oncology at the Vanderbilt-Ingram Cancer Center.  While his general research focus is clinical epidemiology and health services research across all urologic disease, his specific interests include the comparative effectiveness of treatment options in localized prostate cancer and the impact of the disease and its treatment on patients' quality of life. Key Moments: 4 minutes: On the clinical shift to active surveillance. “We have this situation where we were over diagnosing. Half the men who were detected by PSA screening at the turn of the century were overdiagnosed, depending on how you defined overdiagnosis. And they were all getting treated. So you had this terrible problem where we were just kind of treating everybody. I think what we've learned is that, in fact, not everyone with prostate cancer needs to be treated. That PSA picks up a lot of clinically indolent prostate cancer.” 24 minutes: On determining a patient's priorities: “The cancer control and cure piece is not quite as clear [with radiation] because you're not pulling the cancer out. So you don't have the psychological benefit of knowing what you're dealing with. And it's very hard to do surgery after radiation. So it becomes this set of options, a set of what's important to you, right? So patients may not walk in the door saying, ‘I have a preference set.' But as you start talking to them, their preference set becomes relatively clear. And when I talk to them, I say, ‘Listen, I can tell you what I would do,' because a lot of times they say, ‘Doc, what would you do?' But the problem is, I can't take Dave out of Dr. Penson, right? So I have my own set of preferences.” 36 minutes: On emotional vs. rational decision making. “But I think it's very hard to sort of turn down the emotional volume because the word ‘cancer', any human hears that, and it scares you. Right? That goes back to what we were saying before about maybe we shouldn't be calling Gleason 6 cancer, cancer. Because there's a charge that goes with that word that freaks people out.” This episode was supported by the Patient Centered Outcomes Research Institute (PCORI) and features this PCORI study by Dr. Penson. Visit the Manta Cares website  Disclaimer: This podcast is for general informational purposes only and does not constitute the practice of medicine, nursing or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast or materials linked from this podcast is at the user's own risk. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard, or delay in obtaining, medical advice for any medical condition they may have, and should seek the assistance of their health care professionals for any such conditions. --- Support this podcast: https://podcasters.spotify.com/pod/show/manta-cares/support

Howie and Harlan are joined by Zhenqiu Lin, senior director of analytics at Yale's Center for Outcomes Research and Evaluation, to discuss how quality measures can make care more consistent and effective and improve outcomes for patients. Howie provides an update on research on repetitive head trauma among young football players; Harlan reports on new findings about the benefits of semaglutide for people with heart disease. Links: “Neuropathologic and Clinical Findings in Young Contact Sport Athletes Exposed to Repetitive Head Impacts” American Academy Of Pediatrics: “Tackling in Youth Football” “National Use and Effectiveness of β-Blockers for the Treatment of Elderly Patients After Acute Myocardial Infarction” “Twenty-Year Trends in Outcomes for Older Adults With Acute Myocardial Infarction in the United States” “Quality Measure Public Reporting Is Associated with Improved Outcomes Following Hip and Knee Replacement” “Novo Nordisk A/S: Semaglutide 2.4 mg reduces the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity in the SELECT trial” “Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity” Learn more about the MBA for Executives program at Yale SOM. Email Howie and Harlan comments or questions.

Genetics in the dairy industry are making big strides. Project leaders Lauren Brey and Dr. Dan Weigel share about a collaborative project between Edge Dairy Farmer Cooperative, Farmers for Sustainable Food, Zoetis, and 8 aligned farms, showed how focusing on genetic improvement correlates to not only lifetime profitability but reductions in methane intensity, antibiotic usage and feed use on the farm. Dairy Stream host Joanna Guza dives into the topics below with Lauren and Dan: 1:50: How the project got started 2:43: How the farms were selected 5:04: Dairy Wellness Profit Index and how it was used 7:55: Process of collecting and analyzing the data 9:40: The study had 43 percent reduction in antibiotic usage 13:38: The study had 23 percent reduction in the number of replacement heifers 15:00: The study had 15.8 metrics tons of methane reduced per 1,000-cow herd 16:48: The study had a decrease in feed used 19:52: If farms want to participate, what is the timeline and ROI 22:51: How does the research impact the future of sustainable food 25:00: What's next for the future of research and genetics Special thanks to Edge Dairy Farmer Cooperative for sponsoring this episode. About the guests Lauren Brey Lauren is the director of strategic partnerships and sustainability for the Dairy Business Association (DBA) and Edge Dairy Farmer Cooperative. In this role, she serves as managing director of Farmers for Sustainable Food (FSF) and directs their support of farmer-led conservation groups and sustainability projects. Brey is also responsible for fostering relationships with other organizations to bring more value and resources to the members of DBA and Edge. She previously served as the director of marketing and research and worked as a scientist for a cheese company prior to DBA, Edge and FSF.   Dr. Dan Weigel Dan grew up in Iowa on the family farm (Weigeline Holsteins) and graduated from Iowa State University with a BS in Dairy Science.  He received both his MS and PhD from Virginia Tech, with his dissertation focusing on the prediction of genetic merit for lifetime profitability in Holsteins.  Before joining the R&D group of Zoetis (formerly Pfizer Animal Health) in 1995, Dr. Weigel served as a post-doctoral fellow at the University of Guelph working on the implementation of Multiple Across Country Evaluations (MACE) for conformation traits of Holstein sires.  Dr. Weigel's current role with Zoetis is in Outcomes Research and he also remains active as a breeder of dairy cattle.  This podcast is co-produced by the Dairy Business Association and Edge Dairy Farmer Cooperative, sister organizations that fight for effective dairy policy in Wisconsin and Washington, D.C.  Become a sponsor, share an idea or feedback by emailing podcast@dairyforward.com. 

Dr. David Penson, Chair of the Department of Urology at Vanderbilt University, discusses his comparative effectiveness research in prostate cancer. He talks about the evolution of Prostate Cancer awareness in the US, and historic screening and side effect issues that have made it a stigmatized topic for many men. Dr. Penson describes the nuances of PSA testing and how higher diagnosis rates of Prostate Cancer has led to overtreatment in the past, and the current shift to focus on active surveillance is helping to better balance the treatment paradigm for men with Prostate Cancer. Key Highlights: What is comparative effectiveness research and why does it matter to cancer patients? The evolution of the stigma associated with Prostate Cancer. How to think about the nuances of PSA screening tests. About our guest: David F. Penson, MD, MPH is the Hamilton and Howd Chair in Urologic Oncology, Director of the Center for Surgical Quality and Outcomes Research and Professor and Chair, Department of Urology at Vanderbilt University. He currently maintains a clinical practice in urologic oncology at the Vanderbilt-Ingram Cancer Center.  While his general research focus is clinical epidemiology and health services research across all urologic disease, his specific interests include the comparative effectiveness of treatment options in localized prostate cancer and the impact of the disease and its treatment on patients' quality of life. Key Moments: 6 minutes: What is CER and why does it matter? “Comparative effectiveness research has been around forever. People have different names for it, but it's comparing the effectiveness of various interventions for a condition. I've been focused in prostate cancer, so a lot of what I'm focused on is comparing the effectiveness of surgery and radiation and, for that matter, active surveillance in outcomes in prostate cancer.” 21 minutes: How cultural differences impact stigma. “In the US, prostate cancer is much more common in Black men. And the way they respond to the diagnosis may be different than other cultural groups. Hispanic men have another way of looking at it, white men, etc. So you do have this cultural element to it too, because sexuality and body image is often tied to cultural norms.” 31 minutes: The nuances of PSA screening. “The American Urological Association just came out with new recommendations around screening and does say, discuss screening, but doesn't say everyone should be screened. They've sort of started talking about getting a PSA test in your mid-40s, because there's pretty good literature that a baseline PSA test will establish your pretest probability of clinically significant prostate cancer in your lifetime. But the other thing that they mentioned is they basically say we should probably not be doing annual screening with PSA testing, probably every other year. Because less may be more here.” This episode was supported by the Patient Centered Outcomes Research Institute (PCORI) and features this PCORI study by Dr. Penson. Visit the Manta Cares website  Disclaimer: This podcast is for general informational purposes only and does not constitute the practice of medicine, nursing or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast or materials linked from this podcast is at the user's own risk. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard, or delay in obtaining, medical advice for any medical condition they may have, and should seek the assistance of their health care professionals for any such conditions. --- Support this podcast: https://podcasters.spotify.com/pod/show/manta-cares/support

The Dairy Streamlet is a new, condensed version of Dairy Stream that takes the long episode and covers just the high-level points of the conversation. If this topic interests you, we encourage you to listen to the full episode on September 6. Dairy Stream host Joanna Guza talks with project leaders Lauren Brey and Dr. Dan Weigel about a collaborative project focusing on how genetic improvement correlates to not only lifetime profitability but reductions in methane intensity, antibiotic usage and feed use on the farm. Special thanks to Edge Dairy Farmer Cooperative for sponsoring this episode. About the guests Lauren Brey Lauren is the director of strategic partnerships and sustainability for the Dairy Business Association (DBA) and Edge Dairy Farmer Cooperative. In this role, she serves as managing director of Farmers for Sustainable Food (FSF) and directs their support of farmer-led conservation groups and sustainability projects. Brey is also responsible for fostering relationships with other organizations to bring more value and resources to the members of DBA and Edge. She previously served as the director of marketing and research and worked as a scientist for a cheese company prior to DBA, Edge and FSF.   Dr. Dan Weigel Dan grew up in Iowa on the family farm (Weigeline Holsteins) and graduated from Iowa State University with a BS in Dairy Science.  He received both his MS and PhD from Virginia Tech, with his dissertation focusing on the prediction of genetic merit for lifetime profitability in Holsteins.  Before joining the R&D group of Zoetis (formerly Pfizer Animal Health) in 1995, Dr. Weigel served as a post-doctoral fellow at the University of Guelph working on the implementation of Multiple Across Country Evaluations (MACE) for conformation traits of Holstein sires.  Dr. Weigel's current role with Zoetis is in Outcomes Research and he also remains active as a breeder of dairy cattle.  This podcast is co-produced by the Dairy Business Association and Edge Dairy Farmer Cooperative, sister organizations that fight for effective dairy policy in Wisconsin and Washington, D.C.  Become a sponsor, share an idea or feedback by emailing podcast@dairyforward.com. 

Dive into the intricate web of conflicting healthcare incentives. Dr. Wang explains how health economics guides resource allocation for better outcomes. About the Show Welcome to Health Hats, learning on the journey toward best health. I am Danny van Leeuwen, a two-legged, old, cisgender, white man with privilege, living in a food oasis, who can afford many hats and knows a little about a lot of healthcare and a lot about very little. Most people wear hats one at a time, but I wear them all at once.  I'm the Rosetta Stone of Healthcare. We will listen and learn about what it takes to adjust to life's realities in the awesome circus of healthcare.  Let's make some sense of all this. We respect Listeners, Watchers, and Readers. Show Notes at the end. Watch on YouTube Read Newsletter The same content as the podcast but not a verbatim transcript. Could be a book chapter with images. download the printable transcript here Contents Table of Contents Toggle About the ShowWatch on YouTubeRead NewsletterContentsEpisodeProemIntroducing Dr. Yun (Sherry) WangPodcast introMental health research-it's complicatedHealth Economics – How is money spent?From whose point of view? Different reasons to spend moneyDirect and indirect costsSchizophrenia, for exampleUnder- and over-utilizationMedicare and MedicaidHealth Economics for decision makingHealth economics for policymakersThe time frame for economic analysis – years or lifetime?A word from our sponsor, AbridgePlugHealth Economics for advocatesHealth economics and homelessnessIncarcerationCrystal ball gazing far into a lifetimeA more comprehensive viewBuprenorphineStigma and BuprenorphineHome value disparities as an indicatorMapping disparitiesReflectionPodcast OutroProduction TeamOther CreditsLinks and referencesDisclaimerSponsored by AbridgeRelated podcastsCreative Commons Licensing Episode Proem Photo by Rodion Kutsaiev on UnSplash Several guests in this Emerging Adults with Mental Illness series discussed conflicting incentives. What does that even mean? Do incentives mean motivation? Why we do what we do? Are we talking about incentives for patients and caregivers, insurance companies, consultants, vendors, policymakers, clinicians, drug companies, pharmacy benefit companies, employers, or communities? In the last episode with Dr. Amanda Chue, we examined dynamic tensions. Incentives certainly cause tensions. Health Image created in DALL.E care is big business, with massive amounts of money involved, extremely fragmented systems within systems, and much power at stake. No wonder we think of conflicting incentives. The first health economist I knew personally was Jane Sarasohn-Kahn, of Health Populi fame. Full disclosure, Jane introduced me to blogging and suggested my name and brand, Health Hats. Introducing Dr. Yun (Sherry) Wang Photo by Francesco Gallarotti on UnSplash Our guest today is Dr. Yun Wang, who prefers Sherry. Dr. Wang is Assistant Professor in Health Economics and Outcomes Research at Chapman University School of Pharmacy. Before joining Chapman, she worked in global health, epidemiology, social science, clinical pharmacy, health economics, and health service research in Asia, Australia, and America. She is also an Alumni Affiliate at the Center for the Study of Race, Ethnicity & Equity, Washington University in St Louis. Her research interests lie in pharmacoepidemiology and health service research for substance users and chronic disease patients—a perfect guest for us. Podcast intro Welcome to Health Hats, the Podcast. I'm Danny van Leeuwen, a two-legged cisgender old white man of privilege who knows a little bit about a lot of healthcare and a lot about very little. We will listen and learn about what it takes to adjust to life's realities in the awesome circus of healthcare. Let's make some sense of all of this. Health Hats: Sherry, thank you so much for joining us today. I'm excited about this. We met a month or two ago,

Dr. Stephanie Young-Moss received her Doctor of Pharmacy degree from Xavier University of Louisiana College of Pharmacy and a Masters of Health Services Administration with a concentration in Health Economics from The University of Wyoming. She has worked in various areas in pharmacy, Community, Regulatory Compliance, Managed Care, and Health Economics and Outcomes Research.  Over the past 20 years Dr. Stephanie has advocated for decreasing disparities in health care through her volunteer work. She has used her platform to educate families across the U.S. on ways to decrease and eliminate health disparities by incorporating simple wellness and mental health techniques. Dr. Moss has shared her views on international and national podcasts and local television news stations. Dr. Stephanie has served on various boards and volunteer organizations that focus on health equity, decreasing implicit bias, addressing social determinants of health and empowering communities to advocate for their health. Join us for Healthy Habits anytime in podcast and find out more! Connect with Dr. Stephanie at www.drstephanieyomo.com and www.menopauseincolor.com Thanks to our sponsors at BrainLoveHealth.com. Please support UnsilencedVoices.org.  Connect with Word of Mom on Facebook, Instagram and Twitter and email us at info.wordofmomradio@gmail.com for more info. WordofMomRadio.com - sharing the wisdom of women, in business and in life.  

In this episode, Dr. Stephanie Young Moss joins me to discuss handling symptoms of perimenopause and the transition into menopause.    Dr. Stephanie Young Moss received her Doctor of Pharmacy degree from Xavier University of Louisiana College of Pharmacy and a Masters of Health Services Administration with a concentration in Health Economics from The University of Wyoming. She has worked in various areas in pharmacy, Community, Regulatory Compliance, Managed Care, and Health Economics and Outcomes Research. Over the past 20 years Dr. Moss has advocated for decreasing disparities in health care through her volunteer work. She has used her platform to educate families across the U.S. on ways to decrease and eliminate health disparities by incorporating simple wellness and mental health techniques. Dr. Moss has shared her views on international and national podcasts and local television news stations.   Dr. Stephanie is the creator of the websites www.drstephanieyomo.com and www.menopauseincolor.com where you will find practical health and wellness tips, ways to reduce healthcare disparities and tools, tips and resources for women experiencing perimenopause and menopause. She has a community of over 100,000 people on social media.   She is also the owner of Integrative Pharmacy Outcomes and Consulting, which focuses on educating underserved communities on ways to reduce and prevent health disparities.   For nearly 2 decades, Dr. Stephanie has served on various boards and volunteer organizations that focus on health equity, decreasing implicit bias, addressing social determinants of health and empowering communities to advocate for their health. She has served on the boards for The Minority Health Coalition of Marion County and Eskenazi Health Center where she has served as the Clinical Quality Committee Chair, Board Secretary and is currently the Board Treasurer. She resides in Indianapolis, Indiana.   Listen in as we talk about: [2:10] Redefining menopause [3:15] The waiting game between having your period and going through menopause [4:30] What is perimenopause [4:55] Typical age ranges for perimenopause [6:40] Symptoms of menopause [8:55] Looking at the natural side of health [9:25] How to know where you're at in the menopause cycle [10:55] What to do at the beginning signs of perimenopause [17:55] Why we need Hepatitis B shots [20:05] The transition between perimenopause and menopause   Notes from Natalie: Sign Up for Natalie's Newsletter  Seeking Health: www.natalietysdal.com/favorites  Digital Madness: https://amzn.to/44zekUN Glow Kids: https://amzn.to/44gfPaT Connect with Dr. Stephanie Young Moss Instagram: https://www.instagram.com/drstephanieyomo Twitter: https://www.twitter.com/drstephanieyomo  LinkedIn: https://www.linkedin.com/in/stephanieyoungmoss  Facebook: https://www.facebook.com/pharmacistmomsgroup  Website: https://www.drstephanieyomo.com/    Connect with Natalie Instagram: https://www.instagram.com/ntysdal/  YouTube: https://www.youtube.com/@ntysdal Facebook: https://www.facebook.com/NatalieTysdal/  Website: https://www.natalietysdal.com   

To participate in the FOCUS Online study, please visit the following link: https://forms.office.com/r/eXfRT1ZanZ. Matthew Roché, PhD, is the Director of Outcomes Research. Matt earned his PhD in clinical psychology at State University of New York at Binghamton and had pre- and post-doctoral appointments in the Division of Schizophrenia Research at the University of Medicine and Dentistry/Robert Wood Johnson Hospital and Rutgers University. After completing his training, Matt served in Research Specialist and faculty capacities at Rutgers where he worked collaboratively with pharmaceutical, private research, and start-up firms;  worked on scale development for clinical phenomenon in schizophrenia and schizophrenia-spectrum disorders; assisted in protocol development for projects evaluating the role of Huntington's disease, schizophrenia, and Parkinson's disease on retinal cell functioning; and, developed and led trainings on clinical rating scales and diagnostic interviewing. In addition, Matt taught in various graduate (masters and doctoral) programs at Rutgers. Matt is currently an Assistant Professor in the Department of Psychology at New Jersey City University. Matt joined CHDI in 2018.

Jennifer Quinn, Head of global pricing and health economics and outcomes research at Debiopharm, emphasizes the importance of reimbursement, not just regulatory approval, for a drug to be available to patients.  With patient-centered outcomes research, drug developers can use data for risk-benefit assessment relevant to regulators that reflect how patients consider the risks and whether they will undergo a procedure. Jennifer explains, "My team really tries to make sure that, when we're thinking about a clinical development program, we make sure we're capturing those value markers throughout from a very early stage. That is so that when someone out-licenses it and becomes our partner, they have the data they need not just to get through regulatory approval but to have the drug reimbursed and made available to patients." "It's so important that patients have not just the agency in their care, but we understand how treatments are impacting patients -- impacting their lives, impacting how they feel, impacting their activities of daily living. I think that is what patient-centered outcomes research encompasses: patient preference, patient functioning, and patient feeling. If we don't do that, we are not patient-centric in our drug development because we're missing this crucial part. A drug might shrink a tumor this much, or it might give you this many fewer bleeds if you're a hemophilia patient, but what does that mean to the patient? How does that impact them?" @DebiopharmNews #Debiopharm #DrugDevelopment #Biotech #PatientCare #PatientCenteredOutcomesResearch Debiopharm.com Download the transcript here

Jennifer Quinn, Head of global pricing and health economics and outcomes research at Debiopharm, emphasizes the importance of reimbursement, not just regulatory approval, for a drug to be available to patients.  With patient-centered outcomes research, drug developers can use data for risk-benefit assessment relevant to regulators that reflect how patients consider the risks and whether they will undergo a procedure. Jennifer explains, "My team really tries to make sure that, when we're thinking about a clinical development program, we make sure we're capturing those value markers throughout from a very early stage. That is so that when someone out-licenses it and becomes our partner, they have the data they need not just to get through regulatory approval but to have the drug reimbursed and made available to patients." "It's so important that patients have not just the agency in their care, but we understand how treatments are impacting patients -- impacting their lives, impacting how they feel, impacting their activities of daily living. I think that is what patient-centered outcomes research encompasses: patient preference, patient functioning, and patient feeling. If we don't do that, we are not patient-centric in our drug development because we're missing this crucial part. A drug might shrink a tumor this much, or it might give you this many fewer bleeds if you're a hemophilia patient, but what does that mean to the patient? How does that impact them?" @DebiopharmNews #Debiopharm #DrugDevelopment #Biotech #PatientCare #PatientCenteredOutcomesResearch Debiopharm.com Listen to the podcast here

"Dr. Stephanie Young Moss received her Doctor of Pharmacy degree from Xavier University of Louisiana College of Pharmacy and a Masters of Health Services Administration with a concentration in Health Economics from The University of Wyoming. She has worked in a variety of areas in pharmacy including, Community, Regulatory Compliance, Managed Care, and Health Economics and Outcomes Research. Over the past 20 years Dr. Moss has advocated for decreasing disparities in health care through her volunteer work. She has used her platform to educate families across the U.S. on ways to decrease and eliminate health disparities by incorporating simple wellness and mental health techniques. Dr. Moss has shared her views on international and national podcasts and local television news programs. Dr. Stephanie is the creator of the websites www.drstephanieyomo.com and www.menopauseincolor.com where you will find practical health and wellness tips, ways to reduce healthcare disparities and tools, tips and resources for women experiencing perimenopause and menopause. She has a community of over 100,000 people on social media. She is also the owner of Integrative Pharmacy Outcomes and Consulting, which focuses on educating underserved communities on ways to reduce and prevent health disparities. For nearly 2 decades, Dr. Stephanie has served on various boards and volunteer organizations that focus on health equity, decreasing implicit bias, addressing social determinants of health and empowering communities to advocate for their health. She has served on the boards for The Minority Health Coalition of Marion County and Eskenazi Health Center where she served as the Clinical Quality Committee Chair, Board Secretary and is currently the Board Treasurer. She resides in Indianapolis, Indiana."www.magicmomentsplay.com

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with Dilesh Doshi, PharmD, vice president of Health Economic and Outcomes Research at Acadia Pharmaceuticals. He spoke on the advantages and benefits of pimavanserin (Nuplazid; Acadia), the only FDA-approved therapy to treat Parkinson disease psychosis. Additionally, he discussed recent data that compared efficacy and safety of other off-label therapies such as clozapine and quetiapine.  Looking for more Parkinson disease discussion? Check out the NeurologyLive® movement disorder clinical focus page. Episode Breakdown: 1:10 – Mechanistic differences between pimavanserin and other atypical antipsychotics 3:00 – Understanding drug-to-drug interactions for PDP 5:05 – Decision making with quetiapine and negative cognitive effects 7:10 – Improved use of pimavanserin since approval 9:00 – Neurology News Minute 11:40 – Potential predictors of mortality in Parkinson disease psychosis 15:20 – Possibility of preventing PD psychosis 17:20 – Future research on identifying subgroups of responders to treatment This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com. The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Tiziana Announces Planned Phase 2 Study of Foralumab in Progressive Multiple Sclerosis Blarcamesine Deemed Safe, Effective in Phase 2 Extension Study of Parkinson Disease Dementia Eplontersen Continues to Show Clinical Benefit in Long-Term Analysis of hATTR Polyneuropathy Reldesemtiv to be Discontinued in ALS Following Data Monitoring Committee Analysis Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

HRRP stands for Hospital Readmissions Reduction Program, by the way. I wanted to encore this episode with Dr. Rishi Wadhera because it's a great representation of a common root cause reason why quality metrics sometimes don't end well in real life. This root cause is otherwise known as Goodhart's Law, and we dig into Goodhart's law later on in this healthcare podcast. But the actual and ultimate impact of HRRP is also a pretty good representation of the consequences, what happens, when you create a blunt-force policy that assumes hospitals with very different circumstances are the same. Before we kick in to the episode, I asked Dr. Wadhera, my guest today as aforementioned, if there'd been any updates regarding HRRP since this show originally aired last year; and he told me that two key pieces have come out this past month in JAMA journals calling out CMS (Centers for Medicare & Medicaid Services) to move on from/retire this policy: A Decade of Observing the Hospital Readmission Reductions Program—Time to Retire an Ineffective Policy Readmission Reduction as a Hospital Quality Measure: Time to Move on to More Pressing Concerns? Thanks so much to Dr. Steve Schutzer and also BoneDoc66 for your really nice reviews this past month. So appreciated … thank you so much! And here is your encore. Today's guest is Rishi Wadhera, MD, MPP. Dr. Wadhera authored a retrospective analysis in the BMJ about the HRRP, which we will talk about in this healthcare podcast. Dr. Wadhera is a cardiologist at Beth Israel Deaconess Medical Center. He also has a master's in public policy at the Harvard Kennedy School of Government and also a master's in public health from the University of Cambridge. But here's the larger epiphany that pertains to all value-based care and all quality metrics which Dr. Wadhera brings up in this healthcare podcast and which my nerd heart could not love more: Goodhart's Law. This law is the root of so very many problems. Goodhart's Law is this (which I learned from Dr. Wadhera): “When a measure becomes a target, it ceases to be a good measure.” In other words, when we set a goal, people will try to take a shortcut to the goal, regardless of the consequences. And sometimes the consequences, paradoxically, are to do worse at the goal. Maybe because bean counters and admins and maybe even goal-oriented clinicians themselves will go right to the end goal, inadvertently skipping a whole bunch of (it turns out) rate-critical steps. For example, teaching to the test may not lead to students who deeply understand a subject. And anyone trying to achieve value-based care success, improve quality, form collaborations, or make sales might want to remember that old proverb, “Sometimes the shortest way home is the long way around.”   You can learn more at Dr. Wadhera's Harvard Catalyst profile and the Beth Israel Deaconess Medical Center Web site.   Rishi K. Wadhera, MD, MPP, MPhil, is an assistant professor of medicine at Harvard Medical School, a cardiologist at Beth Israel Deaconess Medical Center (BIDMC), and the associate program director of the cardiovascular medicine fellowship at BIDMC. He is also health policy and equity researcher at the Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology. Dr. Wadhera received his MD from the Mayo Clinic School of Medicine as well as an MPhil in public health as a Gates Cambridge Scholar from the University of Cambridge. He completed his internal medicine residency and cardiovascular medicine fellowship at Brigham and Women's Hospital in Boston. During this time, he also received a master's in public policy (MPP) at the Harvard Kennedy School of Government, with a focus on health policy. Dr. Wadhera's research spans questions related to healthcare access, quality, and disparities, as well as understanding how local, state, and national policy initiatives impact care delivery, health equity, and outcomes. Dr. Wadhera has published more than 80 articles to date, and he receives research support from the National Heart, Lung, and Blood Institute (NHLBI) and the National Institutes of Health (NIH)   03:30 What was the Hospital Readmissions Reduction Program intended to do? 05:22 Why did the Centers for Medicare & Medicaid (CMS) think some readmissions were preventable? 06:02 “The spirit of the Hospital Readmissions Reduction Program was to incentivize hospitals to improve … discharge planning, transitions of care, and post-discharge follow-up and care.” 06:58 How has research in the last few years changed the thoughts on the effectiveness of the Hospital Readmissions Reduction Program? 08:16 “The 30-day readmission measure—it's an incomplete measure.” 11:48 “I think patients … are smart, and they know what's going on.” 13:34 “What's happening is, we're just increasing the number of times they need to come back to the ER within that 30-day period.” 13:55 “The weird thing about the HRRP is that when it evaluates hospitals' 30-day readmission rates, it's a yes-no phenomenon.” 15:03 “What CMS does is, it risk adjusts … and that is what we should be doing.” 18:30 “This program has been incredibly regressive.” 19:04 “Poverty, neighborhood disadvantage, housing instability—these factors are out of hospitals' control.” 21:50 “Blunt policies like this that are rolled out nationally probably elicit mixed behavioral responses.” 22:06 “It just makes no sense to take resources away from hospitals.” 22:32 EP295 with Rebecca Etz, PhD. 23:47 What's the way to improve quality of care globally? 25:37 “CMS's approach to improving quality of care has really anchored … [that] to payment.” 26:08 “It's time for us to rethink what our approach to quality improvement should be.” 29:22 “Policy makers have an obligation to rigorously test the impact of these types of policies before they roll them out nationally.” 31:41 Can you scale healthcare nationally?   You can learn more at Dr. Wadhera's Harvard Catalyst profile and the Beth Israel Deaconess Medical Center Web site.   @rkwadhera of @BIDMChealth discusses #HRRP on our #healthcarepodcast. #healthcare #podcast #digitalhealth #vbc #hospitalreadmission What was the Hospital Readmissions Reduction Program intended to do? @rkwadhera of @BIDMChealth discusses #HRRP on our #healthcarepodcast. #healthcare #podcast #digitalhealth #vbc #hospitalreadmission Why did CMS think some readmissions were preventable? @rkwadhera of @BIDMChealth discusses #HRRP on our #healthcarepodcast. #healthcare #podcast #digitalhealth #vbc #hospitalreadmission “The spirit of the Hospital Readmissions Reduction Program was to incentivize hospitals to improve … discharge planning, transitions of care, and post-discharge follow-up and care.” @rkwadhera of @BIDMChealth discusses #HRRP on our #healthcarepodcast. #healthcare #podcast #digitalhealth #vbc #hospitalreadmission How has research in the last few years changed the thoughts on the effectiveness of the Hospital Readmissions Reduction Program? @rkwadhera of @BIDMChealth discusses #HRRP on our #healthcarepodcast. #healthcare #podcast #digitalhealth #vbc #hospitalreadmission “The 30-day readmission measure—it's an incomplete measure.” @rkwadhera of @BIDMChealth discusses #HRRP on our #healthcarepodcast. #healthcare #podcast #digitalhealth #vbc #hospitalreadmission “What CMS does is, it risk adjusts … and that is what we should be doing.” @rkwadhera of @BIDMChealth discusses #HRRP on our #healthcarepodcast. #healthcare #podcast #digitalhealth #vbc #hospitalreadmission “Blunt policies like this that are rolled out nationally probably elicit mixed behavioral responses.” @rkwadhera of @BIDMChealth discusses #HRRP on our #healthcarepodcast. #healthcare #podcast #digitalhealth #vbc #hospitalreadmission “It just makes no sense to take resources away from hospitals.” @rkwadhera of @BIDMChealth discusses #HRRP on our #healthcarepodcast. #healthcare #podcast #digitalhealth #vbc #hospitalreadmission What's the way to improve quality of care globally? @rkwadhera of @BIDMChealth discusses #HRRP on our #healthcarepodcast. #healthcare #podcast #digitalhealth #vbc #hospitalreadmission “It's time for us to rethink what our approach to quality improvement should be.” @rkwadhera of @BIDMChealth discusses #HRRP on our #healthcarepodcast. #healthcare #podcast #digitalhealth #vbc #hospitalreadmission Can you scale healthcare nationally? @rkwadhera of @BIDMChealth discusses #HRRP on our #healthcarepodcast. #healthcare #podcast #digitalhealth #vbc #hospitalreadmission   Recent past interviews: Click a guest's name for their latest RHV episode! Ge Bai (Encore! EP356), Dave Dierk and Stacey Richter (INBW37), Merrill Goozner, Betsy Seals (EP387), Stacey Richter (INBW36), Dr Eric Bricker (Encore! EP351), Al Lewis, Dan Mendelson, Wendell Potter, Nick Stefanizzi, Brian Klepper (Encore! EP335), Dr Aaron Mitchell (EP382), Karen Root, Mark Miller, AJ Loiacono, Josh LaRosa, Stacey Richter (INBW35), Rebecca Etz (Encore! EP295), Olivia Webb (Encore! EP337), Mike Baldzicki, Lisa Bari, Betsy Seals (EP375), Dave Chase, Cora Opsahl (EP373), Cora Opsahl (EP372), Dr Mark Fendrick (Encore! EP308), Erik Davis and Autumn Yongchu (EP371), Erik Davis and Autumn Yongchu (EP370)

Episode 37: Arun Jayaraman, PT, PhD - Exec Director, Tech & Innovation Hub at Shirley Ryan Ability Lab Welcome to the 2022 World Stroke Day edition of the Know Stroke Podcast. David and Mike had the privilege of sitting down with a world renowned expert in stroke rehab technology leading innovation at the #1 ranked rehabilitation hospital in the United States. We hope this episode will bring you optimism knowing that passionate leaders like todays guest are at the helm of clinical research. About Our Guest Arun Jayaraman, PT, PhD, is an internationally recognized expert on sensors, exoskeletons, robotics and other emerging rehabilitation technologies. As Executive Director, Technology & Innovation Hub (tiHUB), he collaborates with commercial and academic partners for research collaboration, technology development and clinical outcome evaluation. He also leverages valuable industry and research expertise to accelerate Shirley Ryan AbilityLab's clinical adoption of next-generation rehabilitation technologies. Since joining Shirley Ryan AbilityLab in 2008, Dr. Jayaraman also has served as Director of the Max Näder Lab for Rehabilitation Technologies and Outcomes Research, which conducts outcomes-based research on rehabilitation technologies such as prostheses, orthoses, rehabilitation robotics and other adaptive technologies. In addition to his work at Shirley Ryan AbilityLab, he is Professor of Physical Medicine, Rehabilitation, Medical Social Sciences, and Physical Therapy and Human Movement Sciences at the Northwestern University Feinberg School of Medicine. Dr. Jayaraman's work has been published in more than 100 peer-reviewed journal articles, and has been funded by myriad leading organizations, including the U.S. Department of Defense, the National Institutes of Health, the National Science Foundation and the Michael J. Fox Foundation. He also holds various external leadership positions, serving as Director of Global Outreach for the Wearable Robotics Association and editorial Board Member for the International Journal of Stroke. Dr. Jayaraman also is involved with the American Orthotic Prosthetic Association, the Society for Neuroscience and the American Physical Therapy Association. Dr. Jayaraman holds a BS in Physical Therapy from SRM Medical College Hospital and Research Centre in Chennai, India; an MS in Physical Therapy from Georgia State University; and a PhD in Rehabilitation Medicine from the University of Florida in Gainesville. Show Mentions and Resources: https://www.world-stroke.org https://brainqtech.com/ https://wolkairbag.com/ https://research.samsung.com/robot#teaser-video https://rewalk.com/restore-exo-suit/ https://www.bbc.com/news/science-environment-43146117 https://www.sralab.org/researchers/arun-jayaraman-pt-phd https://www.sralab.org/services/international-patients Show Credits: Music intro credit to Jake Dansereau, connect at JAKEEZo on Soundcloud @user-257386777. Our intro welcome is the voice of Caroline Goggin, a stroke survivor and our first podcast guest! Please listen to her inspiring story on Episode 2 of the podcast. Thank you Caroline! Our Show is Now on the Health Podcast Network! https://healthpodcastnetwork.com/show/the-know-stroke-podcast/ Until next time, be sure to give the show a like and share, +follow and connect with us on social or contact us to be a guest on the Know Stroke Podcast. Connect with Us and Share our Show on Social: Web Twitter Facebook  Instagram Youtube Linkedin

Audible Bleeding editors Matt Chia and Wen Kawaji are joined by JVS Assistant Editor Dr. Paul Dimuzio and JVS Editor-in-Chief Dr. Thomas Forbes to discuss a recent article in the JVS.  They're joined by Dr. Elizabeth Andraska, the first author of the paper discussing long-term followup after EVAR, available now in the August 2022 issue of the JVS.  Find out how this paper can have an immediate impact on your patients, and hear insights directly from Dr. Andraska in this exciting episode!   Link to “Longer follow-up intervals following endovascular aortic aneurysm repair are safe and appropriate after marked aneurysm sac regression” by Andraska et al.: https://doi.org/10.1016/j.jvs.2022.01.079    Show Guests: Dr. Elizabeth Andraska (@eandraska) is in her sixth year of training in the integrated vascular surgery residency at the University of Pittsburgh. She has a Masters in Clinical Research from the University of Michigan and has completed two years of dedicated research time at the University of Pittsburgh. She is excited to pursue a career in academic vascular surgery.   Previous episode with Dr. Elizabeth Andraska on Getting Started with Basic Science in Vascular Surgery: https://www.audiblebleeding.com/getting-started-in-basic-science/    Previous episode with Dr. Thomas Forbes and Dr. Ron Dalman on the next chapter of the JVS: https://www.audiblebleeding.com/2022/06/14/interview-with-the-incoming-editors-of-the-jvs/    JVS Host Introductions: Dr. Paul Dimuzio (@pdimuziomd) is the William M. Measey Professor of Surgery, Director of the Division of Vascular and Endovascular Surgery at Thomas Jefferson University Hospital and Co-Director of the Jefferson Vascular Center in Philadelphia, as well as being one of the new Assistant Editors for the JVS. Dr. Thomas Forbes (@TL_Forbes) is the Surgeon-in-Chief and James Wallace McCutcheon Chair of the Sprott Department of Surgery at the University Health Network, Professor of Surgery at the University of Toronto, as well as being one of the new Editors-in-Chief for the JVS.   Audible Bleeding Host Introductions:  Dr. Wen Kawaji (@WenKawaji) is a general surgery resident at Medstar Health in Baltimore, MD. She is passionate about vascular, trauma, and critical care and recently completed a burn/surgical critical care fellowship at Johns Hopkins. Wen has been a loyal audible bleeding fan throughout residency and is excited to learn from and work with the podcast team. In her spare time, she enjoys traveling, food adventures, and puzzles. Dr. Matthew Chia (@chia_md) is in his final year of the integrated vascular surgery program at Northwestern University.  He obtained his medical degree from the University of Illinois College of Medicine, and also holds a Master's in Health Services and Outcomes Research at Northwestern.    Follow us @audiblebleeding Learn more about us at https://www.audiblebleeding.com/about-1/ and #jointheconversation.

Welcome to PsychEd, the psychiatry podcast for medical learners, by medical learners. This episode covers perinatal psychiatry with Dr. Tuong Vi Nguyen, Assistant Professor, Department of Psychiatry, Faculty of Medicine and Health Sciences, McGill University and Scientist and Scientist, RI-MUHC, Brain Repair and Integrative Neuroscience (BRaIN) Program, Centre for Outcomes Research and Evaluation.    The learning objectives for this episode are as follows:   By the end of this episode, you should be able to… Define the field of perinatal psychiatry Describe the key issues that should be addressed in pre-conception psychiatric counseling Discuss the management approach for prescribing medications during pregnancy Recognize the prevalence of mood disorders during the perinatal period Recall the diagnostic criteria for postpartum depression Consider the risk factors and explanatory models for postpartum depression Discuss the use of screening tools for postpartum depression Outline the treatment for postpartum depression Describe the clinical presentation of postpartum psychosis and recognize the urgency of this condition List important risk factors for postpartum psychosis Discuss the management for postpartum psychosis   Guest: Dr. Tuong Vi Nguyen   Hosts: Nima Nahiddi (PGY4), Audrey Le (PGY1), and Arielle Geist (PGY2)    Produced by: Nima Nahiddi (PGY4), Audrey Le (PGY1), Rebecca Marsh (PGY2) and Arielle Geist (PGY2)    Audio editing by: Audrey Le   Show notes by: Arielle Geist    Interview content: Introduction - 00:00 Learning objectives - 00:43 Defining the field of perinatal psychiatry - 01:55 Key issues to address in preconception counseling - 02:50 Management approach for prescribing medications during pregnancy - 07:00 Prevalence of mood disorders during the perinatal period - 12:11 Diagnostic criteria for postpartum depression - 14:05 Differentiating postpartum psychosis from postpartum depression - 16:52 Risk factors and explanatory models for postpartum depression - 18:58 Screening tools for postpartum depression - 20:15 Treatment for postpartum depression - 22:13 Pharmacotherapy - 22:20 Psychotherapy - 27:34 Clinical presentation of postpartum psychosis - 29:07 Risk factors for postpartum psychosis - 30:43 Postpartum psychosis prognosis and impacts on attachment- 32:57 Management of postpartum psychosis -35:30 Closing comments - 38:00   Resources: Bérard, A., Zhao, J. P., & Sheehy, O. (2017). Antidepressant use during pregnancy and the risk of major congenital malformations in a cohort of depressed pregnant women: an updated analysis of the Quebec Pregnancy Cohort. BMJ open, 7(1), e013372. https://doi.org/10.1136/bmjopen-2016-013372 Boukhris, T., Sheehy, O., Mottron, L., & Bérard, A. (2016). Antidepressant Use During Pregnancy and the Risk of Autism Spectrum Disorder in Children. Jama Pediatrics, 170(2), 117-24. doi: 10.1001/jamapediatrics.2015.3356. Brown, A. S., Gyllenberg, D., Malm, H., McKeague, I. W., Hinkka-Yli-Salomäki, S., Artama, M., Gissler, M., Cheslack-Postava, K., Weissman, M. M., Gingrich, J. A., & Sourander, A. (2016). Association of Selective Serotonin Reuptake Inhibitor Exposure During Pregnancy With Speech, Scholastic, and Motor Disorders in Offspring. JAMA psychiatry, 73(11), 1163–1170. https://doi.org/10.1001/jamapsychiatry.2016.2594 Cohen, J. , Hernández-Díaz, S. , Bateman, B. , Park, Y. , Desai, R. , Gray, K. , Patorno, E. , Mogun, H. & Huybrechts, K. (2017). Placental Complications Associated With Psychostimulant Use in Pregnancy. Obstetrics & Gynecology, 130(6), 1192-1201. doi: 10.1097/AOG.0000000000002362. Huybrechts, K. F., Hernández-Díaz, S., Patorno, E., Desai, R. J., Mogun, H., Dejene, S. Z., Cohen, J. M., Panchaud, A., Cohen, L., & Bateman, B. T. (2016). Antipsychotic Use in Pregnancy and the Risk for Congenital Malformations. JAMA psychiatry, 73(9), 938–946. https://doi.org/10.1001/jamapsychiatry.2016.1520 Huybrechts, K. F., Palmsten, K., Avorn, J., Cohen, L. S., Holmes, L. B., Franklin, J. M., Mogun, H., Levin, R., Kowal, M., Setoguchi, S., & Hernández-Díaz, S. (2014). Antidepressant use in pregnancy and the risk of cardiac defects. The New England Journal of Medicine, 370(25), 2397–2407. https://doi.org/10.1056/NEJMoa1312828 Imaz, M. L., Oriolo, G., Torra, M., Soy, D., García-Esteve, L., & Martin-Santos, R. (2018). Clozapine Use During Pregnancy and Lactation: A Case-Series Report. Frontiers in Pharmacology, 9, 264. https://doi.org/10.3389/fphar.2018.00264 Nörby, U., Forsberg, L., Wide, K., Sjörs, G., Winbladh, B., & Källén, K. (2016). Neonatal Morbidity After Maternal Use of Antidepressant Drugs During Pregnancy. Pediatrics, 138(5), e20160181. https://doi.org/10.1542/peds.2016-0181 Nörby, U., Winbladh, B., & Källén, K. (2017). Perinatal Outcomes After Treatment With ADHD Medication During Pregnancy. Pediatrics, 140(6), e20170747. https://doi.org/10.1542/peds.2017-0747 Reis, M., & Källén, B. (2013). Combined use of selective serotonin reuptake inhibitors and sedatives/hypnotics during pregnancy: risk of relatively severe congenital malformations or cardiac defects. A registered study. BMJ Open, 3, e002166. doi:10.1136/bmjopen-2012-002166 Sundram S. (2006). Cannabis and neurodevelopment: implications for psychiatric disorders. Human psychopharmacology, 21(4), 245–254. https://doi.org/10.1002/hup.762   References: Boland, R., Verduin, M., & Ruiz, P. (2021). Psychopharmacology. In Kaplan & Sadock's synopsis of psychiatry (Twelfth edition.). Philadelphia: Wolters Kluwer. Jones, I., Chandra, P.S., Dazzan, P., & Howard, L.K. (2014). Bipolar disorder, affective psychosis, and schizophrenia in pregnancy and the post-partum period. Lancet, 384(9956), 1789-1799. doi: 10.1016/S0140-6736(14)61278-2. Nieldson, D., Videbech, P., Hedegaard, M., Dalby, J., & Secher, N.J. (2005). Postpartum depression: identification of women at risk. An International Journal of Obstetrics and Gynaecology, 107(10), 1210-1217. https://doi-org.myaccess.library.utoronto.ca/10.1111/j.1471-0528.2000.tb11609.x Schiller, C.E., Meltzer-Brody, S., & Rubinow, D.R. (2015). The role of reproductive hormones in postpartum depression. CNS Spectrums, 20(1), 48-59. doi: 10.1017/S1092852914000480 Viguera, A. (2021). Mild to moderate postpartum unipolar major depression: Treatment. UpToDate. Accessed 2021-01-18. Wisner, K.L., Sit, D.K.Y., & McShea, M.C. (2013). Onset timing, thoughts of self-harm, and diagnoses in postpartum women with screen-positive depression findings. JAMA Psychiatry, 70(5), 490-498. doi:10.1001/jamapsychiatry.2013.87   CPA Note: The views expressed in this podcast do not necessarily reflect those of the Canadian Psychiatric Association. For more PsychEd, follow us on Twitter (@psychedpodcast), Facebook (PsychEd Podcast), and Instagram (@psyched.podcast). You can provide feedback by email at psychedpodcast@gmail.com. For more information, visit our website at psychedpodcast.org.

Today I want to highlight the work of another pharmacy and entrepreneur colleague, Dr. Stephanie Young Moss (aka “Yomo”). She caught my eye on Instagram, where she shines her light on wellness, family dynamics, pharmacy practice, and disparities in healthcare. A practical tip that she shared in the episode has stuck with me, about how learning goes both ways. For example, shadowing allows healthcare students to learn from professionals, but the mentors also get the opportunity to learn. A relationship with someone different than you helps you understand where they're coming from and how you can serve different populations. Dr. Stephanie received her Doctor of Pharmacy degree from Xavier University of Louisiana College of Pharmacy and a Masters of Health Services Administration with a concentration in Health Economics from The University of Wyoming. She has worked in various areas in pharmacy, Community, Regulatory Compliance, Managed Care, and Health Economics and Outcomes Research. Over the past 20 years Dr. Moss has advocated for decreasing disparities in health care through her volunteer work. She uses her platform to educate families across the U.S. on ways to decrease and eliminate health disparities by incorporating simple wellness and mental health techniques. Dr. Moss has shared her views on international and national podcasts and local television news stations. Dr. Stephanie is the creator of the website www.drstephanieyomo.com where you will find practical health and wellness tips, ways to reduce healthcare disparities and simple tips for health and wellness professionals to enhance their presence on social media so they can stand out in their niche, build a successful brand and advocate for important causes. She is also the owner of Integrative Pharmacy Outcomes and Consulting, which focuses on educating underserved communities on ways to reduce and prevent health disparities. For nearly 2 decades, Dr. Stephanie has served on various boards and volunteer organizations that focus on health equity, decreasing implicit bias, addressing social determinants of health and empowering communities to advocate for their health. She has served on the boards for The Minority Health Coalition of Marion County and Eskenazi Health Center where she has served as the Clinical Quality Committee Chair, Board Secretary and is currently the Board Treasurer. She resides in Indianapolis, Indiana. You can connect with Dr. Yomo on all social media (@Dr. Stephanie Yomo) and www.drstephanieyomo.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

Today I want to highlight the work of another pharmacy and entrepreneur colleague, Dr. Stephanie Young Moss (aka “Yomo”). She caught my eye on Instagram, where she shines her light on wellness, family dynamics, pharmacy practice, and disparities in healthcare. A practical tip that she shared in the episode has stuck with me, about how learning goes both ways. For example, shadowing allows healthcare students to learn from professionals, but the mentors also get the opportunity to learn. A relationship with someone different than you helps you understand where they're coming from and how you can serve different populations. Dr. Stephanie received her Doctor of Pharmacy degree from Xavier University of Louisiana College of Pharmacy and a Masters of Health Services Administration with a concentration in Health Economics from The University of Wyoming. She has worked in various areas in pharmacy, Community, Regulatory Compliance, Managed Care, and Health Economics and Outcomes Research. Over the past 20 years Dr. Moss has advocated for decreasing disparities in health care through her volunteer work. She uses her platform to educate families across the U.S. on ways to decrease and eliminate health disparities by incorporating simple wellness and mental health techniques. Dr. Moss has shared her views on international and national podcasts and local television news stations. Dr. Stephanie is the creator of the website www.drstephanieyomo.com where you will find practical health and wellness tips, ways to reduce healthcare disparities and simple tips for health and wellness professionals to enhance their presence on social media so they can stand out in their niche, build a successful brand and advocate for important causes. She is also the owner of Integrative Pharmacy Outcomes and Consulting, which focuses on educating underserved communities on ways to reduce and prevent health disparities. For nearly 2 decades, Dr. Stephanie has served on various boards and volunteer organizations that focus on health equity, decreasing implicit bias, addressing social determinants of health and empowering communities to advocate for their health. She has served on the boards for The Minority Health Coalition of Marion County and Eskenazi Health Center where she has served as the Clinical Quality Committee Chair, Board Secretary and is currently the Board Treasurer. She resides in Indianapolis, Indiana. You can connect with Dr. Yomo on all social media (@Dr. Stephanie Yomo) and www.drstephanieyomo.com. Quote: “Creating exposure and building professional relationships with someone different than you helps you understand them and their needs.” For more amazing content, visit us at https://drmarinabuksov.com. Music: https://www.purple-planet.com.

In this episode, we are fortunate to hear three interviews from guest experts in the field discussing occupational hazards in vascular surgery. We cover physical pain and discomfort with Dr. Max Wohlauer, radiation safety with Dr. Melissa Kirkwood, and pregnancy and radiation with Dr. Venita Chandra.  Show Guests: Dr. Max Wohlauer (@doctormaxw) is an assistant professor at the University of Colorado School of Medicine, as well as an associate program director of their residency and fellowship.  He founded the Vascular Surgery COVID-19 Collaborative (VASCC, https://medschool.cuanschutz.edu/surgery/divisions-centers-affiliates/vascular/research/vascc/vascc).  He obtained his medical degree from the Albany Medical College and completed general surgery residency at the University of Colorado followed by vascular surgery fellowship at the Cleveland Clinic. Audible Bleeding with Dr. Samuel Money on Ergonomics in Surgery: https://www.audiblebleeding.com/money-ergonomics/  Physical discomfort, professional satisfaction, and burnout in vascular surgeons: https://doi.org/10.1016/j.jvs.2018.11.026  Physical pain and musculoskeletal discomfort in vascular surgeons: https://doi.org/10.1016/j.jvs.2020.07.097  Vascular surgeon wellness and burnout: A report from the Society for Vascular Surgery Wellness Task Force: https://doi.org/10.1016/j.jvs.2020.10.065  Dr. Melissa Kirkwood is an associate professor at the UT Southwestern Medical Center and chief of the division of vascular surgery. She completed her medical degree at Yale University School of Medicine, followed by a general surgery residency at The University of Chicago, and vascular surgery fellowship at the University of Pennsylvania Medical Center. One of her major research interests is radiation dose control and novel technology for decreasing radiation exposure. Dual fluoroscopy with live-image digital zooming significantly reduces patient and operating staff radiation during fenestrated-branched endovascular aortic aneurysm repair: https://doi.org/10.1016/j.jvs.2020.05.031  Disposable, lightweight shield decreases operator eye and brain radiation dose when attached to safety eyewear during fluoroscopically guided interventions: https://doi.org/10.1016/j.jvs.2021.11.067  Radiation brain dose to vascular surgeons during fluoroscopically guided interventions is not effectively reduced by wearing lead equivalent surgical caps: https://doi.org/10.1016/j.jvs.2017.12.054    Dr. Venita Chandra (@ChandraVenita) is a clinical associate professor at Stanford University as well as the program director for vascular surgery residency and fellowship. She obtained her medical degree from the University of Chicago followed by general surgery residency and vascular surgery fellowship at Stanford University. She also completed a technology development fellowship in the Stanford Biodesign Program. She is part of the SVS Wellness Task Force and has an interest in radiation safety in pregnancy. Monitoring of fetal radiation exposure during pregnancy: https://doi.org/10.1016/j.jvs.2013.01.052 Incidence of Infertility and Pregnancy Complications in US Female Surgeons: https://doi.org/10.1001/jamasurg.2021.3301   Host Introductions: Dr. Matt Chia (@chia_md) is in his 6th year in the integrated vascular surgery program at Northwestern University. He obtained his medical degree from the University of Illinois College of Medicine, and also holds a Master's in Health Services and Outcomes Research from Northwestern.    Dr. Jessie Ho (@JessieHo_) is in her 4th year general surgery resident at Northwestern University. She obtained her medical degree from the Texas A&M College of Medicine, and is completing a Master's in Clinical Investigation at Northwestern.   Authors: Matt Chia, MD, MS, Jessie Ho, MD, Janhavi Patel, BMSc Editor: Matt Chia, MD Reviewers: Sharif Ellozy, MD, Adam Johnson, MD